Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

NeoIDC

Financiado

Neoantigen Identification with Dendritic Cell Reprogramming

In cancer, genetic mutations result in production of tumor neoantigens restrictively expressed in transformed cells and serve as ideal molecular targets for cancer vaccines and adoptive T cell therapies. However, available methods... ver más

30/09/2024

LUNDS UNIVERSITET

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

LUNDS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-09-30

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

LUNDS UNIVERSITET

150.00K€ | Lider

Proyectos interesantes

Mel-Immune An integrative genetic approach for the exploration of melan... 3M€ Cerrado

CAN-IT-BARRIERS Disruption of systemic and microenvironmental barriers to i... 3M€ Cerrado

MIMIC Molecular mimicry as a key parameter shaping T cell immunity 2M€ Cerrado

TrojanDC TrojanDC - A BREAKTHROUGH DEEP-TECH INNOVATION FOR CANCER IM... 75K€ Cerrado

RIPECROP RNA-based cancer ImmunotheraPeutics to Enhance CROssPrimming 3M€ Cerrado

PDT-NEO-immunother Generation of tumor neoantigens with photodynamic therapy: a... 176K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 18 meses Fecha Inicio: 2023-03-01
Fecha Fin: 2024-09-30

Líder del proyecto

LUNDS UNIVERSITET

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto In cancer, genetic mutations result in production of tumor neoantigens restrictively expressed in transformed cells and serve as ideal molecular targets for cancer vaccines and adoptive T cell therapies. However, available methods for the identification of clinically relevant neoantigens driving potent anti-tumor immunity are highly inefficient. Thus, there is an urgent need for innovative solutions to identify powerful immunogenic neoantigens to unlock the full potential of immunotherapy and treat currently untreatable cancers. The NeoIDC platform has the radical vision to use the type 1 conventional dendritic cell (cDC1) reprogramming technology, arising from the ERC-funded project TrojanDC, to directly identify highly immunogenic tumor neoantigens and neoantigen-specific T cell receptors (TCRs) for the development of powerful cancer vaccines and adoptive T cell therapies. To achieve this, we will firstly identify tumor peptides presented on MHC class I and II by cDC1-reprogrammed cancer cells and validate immunogenicity in vivo. Secondly, we will expand neoantigen-specific T cells by co-culture with reprogrammed cancer cells, sequence TCRs and link to cognate neoantigens. This will facilitate the generation of potent cancer vaccines and tumor-reactive T cells for adoptive transfer. Experimental activities with collaborators and clinicians will be coupled with exploitation plans including partnership with Asgard Therapeutics, ensuring commercialization by generation of novel IP, broad and targeted dissemination and a new start-up company. NeoIDC combines cDC1’s antigen processing and presenting abilities with the unique mutational profile of cancer cells to enable the direct identification of immunogenic neoantigens and cognate TCRs. Ultimately, this project will enable the development of the next generation of neoantigen-based vaccines and adoptive T cell therapies and will set the stage for a new era of safe, personalized and effective cancer immunotherapies.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores